Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis

Nephrology Dialysis Transplantation

Volumn 32, Issue 1, 2017, Pages 73-80

  De Jong, Maarten A ^a   Mirkovic, Katarina ^a   Mencke, Rik ^a   Hoenderop, Joost G ^b   Bindels, Rene J ^b   Vervloet, Marc G ^c   Hillebrands, Jan Luuk ^a   Van Den Born, Jacob ^a   Navis, Gerjan ^a   De Borst, Martin H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

FGF23; Klotho; RAAS; Renal fibrosis; UUO

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; LOSARTAN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 23; RENIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION; URETER OBSTRUCTION; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; METABOLISM; PATHOLOGY; URETERAL OBSTRUCTION;

ALDOSTERONE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; FIBROSIS; LOSARTAN; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TUMOR NECROSIS FACTOR-ALPHA; URETERAL OBSTRUCTION;

EID: 85016195765     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw105     Document Type: Article

References (18)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113): S1-S2
2. De Borst MH, Vervloet MG, ter Wee PM et al. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am SocNephrol 2011; 22: 1603-1609
3. Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ et al. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade. Am J Kidney Dis. 2015; 65: 259-266
4. Zoccali C, Ruggenenti P, Perna A et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22: 1923-1930
5. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J AmSoc Nephrol 2007; 18: 2600-2608
6. Lundberg S, Qureshi AR, Olivecrona S et al. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol 2012; 7: 727-734
7. Isakova T, Xie H, Yang W et al. FIbroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
8. Böhm M, Lee M, Kreutz R et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 1995; 13: 891-899. http://journals.lww. com/jhypertension/Fulltext/1995/08000/Angiotensin-II-receptor-blockade -in-TGR-mREN2-27-.10.aspx
9. Krebs C, Hamming I, Sadaghiani S et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 2007; 72: 725-730
10. Dai B, David V, Martin A et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One 2012; 7: e44161.
11. Crackower Ma, Sarao R, Oudit GY et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828
12. Reich HN, Oudit GY, Penninger JMet al. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 2008; 74: 1610-1616
13. Yoon HE, Ghee JY, Piao S et al. Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 2011; 26: 800-813
14. Izquierdo MC, Perez-Gomez MV, Sanchez-Nino MD et al. Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant 2012; 27(Suppl 4): iv6-iv10
15. Yang J, Dai C, Liu Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002; 13: 2464-2477
16. Kellner D, Chen J, Richardson I et al. Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. J Urol 2006; 176: 806-812
17. Farrow EG, Davis SI, Summers LJ et al. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009; 20: 955-960
18. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009; 75: 1145-1152